People Say These Peptides Hurt Them. Their Stories Are Muffled in MAHA’s Push for Medical Freedom.
After the third day of squirting an experimental drug up his nose, Dylan Meetze felt…
After the third day of squirting an experimental drug up his nose, Dylan Meetze felt horrible. “It was like I was underwater, like it took the most to do anything,” he said. Meetze stopped taking the drug but endured fatigue and anxiety for months afterward, and his eyes and muscles twitched, he said. He had…
The U.S. Senate candidates in Texas could hardly be more different: James Talarico, a former seminarian turned Democratic state lawmaker who speaks in calm cadences about love and empathy, and Ken Paxton, the pugnacious Republican state attorney general who speaks about a refusal to compromise. They share an enemy, though. They dislike social media’s effects…
When Carol Daniel, a veteran broadcast journalist who lives near St. Louis, was diagnosed with thyroid cancer in 2022, her husband encouraged her to seek a second opinion. She was worried that consulting another doctor might seem like a betrayal. Daniel said she wondered: “Am I cheating on him? Am I going behind his back?…
Health care’s AI future is being built right now. The open question is “for whom?” Dr. Uché Blackstock — emergency physician, former associate professor at NYU School of Medicine, founder and CEO of Advancing Health Equity, and author of The New York Times bestseller “Legacy: A Black Physician Reckons with Racism in Medicine” — joins…
HIE is creating dashboards to identify who’s most at risk of losing coverage and who might fall into the exemption categories
By JOHN SAMARAS Most employers still won’t cover GLP-1s for weight loss, and some of them now tell the employee where to buy them without the plan. The International Foundation of Employee Benefit Plans’ 2026 survey, published in July, found that 60 percent of employers cover the drugs for diabetes only and 36 percent for…
New reports examine state spending, progress and oversight
Asahi Kasei’s Hovilpri is now approved for treating lesions caused by herpes simplex virus infection. This daily pill came from the $919 million acquisition of AiCuris Anti-Infective Cures. The post Asahi Kasei Acquisition Pays Off With FDA Approval for Novel Herpes Drug appeared first on MedCity News.
Outro’s funding included participation from Listen Ventures, Cake Ventures, Jason Calicanis’s LAUNCH, Actions Capital, Hannah Grey Ventures, SemperVirens, Brock Recovery Group and Pave Health Ventures. The post Outro Raises $7M To Support Safe Deprescribing appeared first on MedCity News.
Investing in pediatric care is not simply a moral imperative. It is one of the most practical long-term investments the healthcare system can make. The post Pediatric Innovation Isn’t a Small-Market Problem, It’s an Incentive Problem appeared first on MedCity News.